UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045192
Receipt number R000051627
Scientific Title Effect on immunity by taking enzyme supplements derived from 65 kinds of plants and 12 kinds of lactic acid bacteria: a randomized, double blind, placebo-controlled study
Date of disclosure of the study information 2021/08/23
Last modified on 2023/03/29 10:18:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect on immunity by taking enzyme supplements derived from 65 kinds of plants and 12 kinds of lactic acid bacteria

Acronym

OM-X immunity study

Scientific Title

Effect on immunity by taking enzyme supplements derived from 65 kinds of plants and 12 kinds of lactic acid bacteria: a randomized, double blind, placebo-controlled study

Scientific Title:Acronym

Effect on immunity by taking enzyme supplements derived from 65 kinds of plants and 12 kinds of lactic acid bacteria

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Effect of test article intake on immunity

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Subjective evaluation

Key secondary outcomes

QOL scale


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Take the test article for 12 weeks

Interventions/Control_2

Take the placebo for 12 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

Subjects who often suffer from colds, those who are more likely to get sick than before

Key exclusion criteria

1.Subjects with food allergies
2.Pregnant women, lactating women, and those who are planning to become pregnant during the test period
3.Subjects who are currently going to the hospital or receiving a doctor's prescription due to chronic illness
4.Subjects who have a serious illness
5.Subjects who are receiving hormone replacement therapy
6.Subjects who have been diagnosed with chronic fatigue (chronic fatigue syndrome)
7.Subjects who are taking supplements / medicines that affect the effect of the test product

Target sample size

36


Research contact person

Name of lead principal investigator

1st name Masatomo
Middle name
Last name Najima

Organization

Japan Clinical Trial Association

Division name

N.A.

Zip code

1600022

Address

5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo

TEL

0364574666

Email

info@yakujihou.org


Public contact

Name of contact person

1st name Takeshi
Middle name
Last name Kaneko

Organization

Japan Clinical Trial Association

Division name

N.A.

Zip code

1600022

Address

5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo

TEL

0364574666

Homepage URL


Email

info@yakujihou.org


Sponsor or person

Institute

Japan Clinical Trial Association

Institute

Department

Personal name



Funding Source

Organization

BIOBANK CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Pharmaceutical Law Wisdoms

Address

5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo

Tel

0364574911

Email

master@yakujihou.net


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 08 Month 23 Day


Related information

URL releasing protocol

https://isom.ca/article/immunomodulating-effect-of-om-x-fermented-plant-extract/

Publication of results

Published


Result

URL related to results and publications

https://isom.ca/article/immunomodulating-effect-of-om-x-fermented-plant-extract/

Number of participants that the trial has enrolled

39

Results

As for SF-8, 5 items out of 10 increased significantly in Active, though the Placebo showed a significant decrease in GH. In addition, intergroup analysis depicted significant differences in 6 items . With reference to physical condition, lassitude and sum total of symptoms in Active, and nasal congestion in Placebo showed significant differences after 12 weeks of ingestion. There were significant differences between the two groups in nasal congestion, lassitude, and the sum total of symptoms.

Results date posted

2023 Year 03 Month 29 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

A group: n=19
B group: n=20

Participant flow

Of the 40 subjects who enrolled, 39 completed the study. There was a high level of adherence to the study protocol, with all subjects consuming their assigned test food, The data obtained from 39 subjects (Group A; 19, Group B; 20) were used for efficacy analysis. The subjects were 50.7 +- 4.8 years of age. There were no significant differences in gender ratio or age at baseline between groups.

Adverse events

none

Outcome measures

Subjective evaluation (physical condition)
QOL scale (SF-8)

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 04 Month 16 Day

Date of IRB

2021 Year 08 Month 11 Day

Anticipated trial start date

2021 Year 08 Month 23 Day

Last follow-up date

2021 Year 11 Month 15 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 08 Month 18 Day

Last modified on

2023 Year 03 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051627


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name